Stemline Therapeutics Inc (STML) Holdings Trimmed by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in shares of Stemline Therapeutics Inc (NASDAQ:STML) by 5.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 81,914 shares of the biopharmaceutical company’s stock after selling 4,282 shares during the period. Bank of New York Mellon Corp owned approximately 0.33% of Stemline Therapeutics worth $909,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of STML. Voya Investment Management LLC purchased a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $102,000. Nationwide Fund Advisors raised its stake in shares of Stemline Therapeutics by 7.2% in the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 855 shares during the period. State of Wisconsin Investment Board purchased a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $147,000. Alliancebernstein L.P. purchased a new position in shares of Stemline Therapeutics in the 2nd quarter valued at $178,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Stemline Therapeutics by 40.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 5,522 shares during the period. 50.24% of the stock is currently owned by institutional investors and hedge funds.

In related news, COO Kenneth Hoberman sold 11,943 shares of Stemline Therapeutics stock in a transaction on Friday, December 15th. The shares were sold at an average price of $14.18, for a total transaction of $169,351.74. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 37,966 shares of company stock worth $534,848 in the last ninety days. 15.70% of the stock is currently owned by insiders.

A number of brokerages have recently commented on STML. BidaskClub raised shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. HC Wainwright set a $38.00 target price on shares of Stemline Therapeutics and gave the company a “buy” rating in a research note on Thursday, December 14th. Finally, Cowen reissued a “buy” rating on shares of Stemline Therapeutics in a research note on Tuesday, October 31st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $33.75.

Stemline Therapeutics Inc (NASDAQ:STML) opened at $14.10 on Friday. Stemline Therapeutics Inc has a one year low of $5.50 and a one year high of $16.20. The company has a market cap of $356.55, a price-to-earnings ratio of -5.49 and a beta of -0.02.

ILLEGAL ACTIVITY NOTICE: “Stemline Therapeutics Inc (STML) Holdings Trimmed by Bank of New York Mellon Corp” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thestockobserver.com/2018/01/13/stemline-therapeutics-inc-stml-holdings-trimmed-by-bank-of-new-york-mellon-corp.html.

Stemline Therapeutics Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Institutional Ownership by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply